Emily (Xianghong) Jing
CDER, FDA
Emily (Xianghong) Jing earned her Ph.D. in microbiology and immunology from University of Illinois and completed post-doctoral studies in the virology field at Northwestern University. She joined the US FDA’s office of Vaccine Research and Review (OVRR) in Center for Biologics Evaluation and Research (CBER) as a product quality reviewer in 2009 and moved to Office of Biotechnology products (OBP) in Center for Drug Evaluation and Research (CDER) in 2014. She became a review chief in OBP from year 2018 overseeing the regulatory review of Chemistry, Manufacturing and Control (CMC) sections for a variety of investigational New Drug Applications (INDs), Biologics License Applications (BLAs), biosimilars, transition product (e.g. Insulins), and COVID-19 related INDs & EUA. She has participated prior approval inspections on biologic product manufacturing facilities domestically and internationally.